Zar Technology Services

Belkins
At OPXBIO, we’re in the Good Chemistry business. We develop and produce bio-based chemicals and fuels that deliver more sustainable value to our customers. Good Chemistry is everything we do. It is how we use our leading EDGE™ biotechnology to bring new products to market faster. It’s our strategic partnerships. It’s our high-performing team. And it’s our inspiration to transform the business of chemistry to a more sustainable future.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOTECHS WORKING CLOSELY & FEVERISHLY WITH CDC FOR COVID-19 VACCINE DEVELOPMENT

PR Newswire | April 07, 2020

news image

Many companies searching for an effective therapy or vaccine for the present world health crisis are focusing on creating a vaccine from the immune system. Key to the race to develop a vaccine for the new coronavirus is a technology that uses the virus' genetic code to essentially persuade your body to make its own vaccine. This technique is faster than egg-based manufacturing, which produces the majority of annual flu vaccines… And it's enabling a possible vaccine for the new cor...

Read More

CELL AND GENE THERAPY

C-LECTA CONTINUES ITS GROWTH IN 2021 AND SEES ITSELF EXCELLENTLY POSITIONED FOR THE FUTURE WITH THE ENESYZ TECHNOLOGY PLATFORM

c-LEcta | December 20, 2021

news image

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021. The high expectations for the fiscal year have been fully met and were even significantly exceeded. Thus, the management expects annual revenue in the range of EUR 20 million, which equates to a doubling of last year’s result. With an expanded team, further investments in the product range and the ENESYZ technology platform are expected to keep ...

Read More

TEVOGEN BIO PARTNERED WITH NEAL FLOMENBERG TO EVALUATE TEVOGEN' S PROPRIETARY ANTIGEN-SPECIFIC T-CELL TECHNOLOGY AS A TREATMENT FOR COVID-19

Tevogen Bio | August 11, 2020

news image

Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...

Read More

INDUSTRIAL IMPACT

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

news image

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More
news image

BIOTECHS WORKING CLOSELY & FEVERISHLY WITH CDC FOR COVID-19 VACCINE DEVELOPMENT

PR Newswire | April 07, 2020

Many companies searching for an effective therapy or vaccine for the present world health crisis are focusing on creating a vaccine from the immune system. Key to the race to develop a vaccine for the new coronavirus is a technology that uses the virus' genetic code to essentially persuade your body to make its own vaccine. This technique is faster than egg-based manufacturing, which produces the majority of annual flu vaccines… And it's enabling a possible vaccine for the new cor...

Read More
news image

CELL AND GENE THERAPY

C-LECTA CONTINUES ITS GROWTH IN 2021 AND SEES ITSELF EXCELLENTLY POSITIONED FOR THE FUTURE WITH THE ENESYZ TECHNOLOGY PLATFORM

c-LEcta | December 20, 2021

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021. The high expectations for the fiscal year have been fully met and were even significantly exceeded. Thus, the management expects annual revenue in the range of EUR 20 million, which equates to a doubling of last year’s result. With an expanded team, further investments in the product range and the ENESYZ technology platform are expected to keep ...

Read More
news image

TEVOGEN BIO PARTNERED WITH NEAL FLOMENBERG TO EVALUATE TEVOGEN' S PROPRIETARY ANTIGEN-SPECIFIC T-CELL TECHNOLOGY AS A TREATMENT FOR COVID-19

Tevogen Bio | August 11, 2020

Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...

Read More
news image

INDUSTRIAL IMPACT

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More